No vavax is cel e brat ing tri al re sults again four years af ter a Phase III fail ure in RSV sent their stock price off a cliff.
The com pa ny an nounced that their re com bi nant flu vac cine NanoFlu met all pri ma ry and sec ondary end points in a Phase III study of 2,652 adults old er than 65. The num bers, No vavax sug gest ed, should al low them to clear reg u la to ry hur dles and snag the biotech’s first ap proval since its found ing in 1987.